Suárez Norma, Ferrara Florencia, Rial Analia, Dee Valerie, Chabalgoity Jose A
Departamento de Desarrollo Biotecnológico, Instituto de Higiene, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay.
Front Bioeng Biotechnol. 2020 Jun 5;8:545. doi: 10.3389/fbioe.2020.00545. eCollection 2020.
Bacterial lysates, prepared from the microorganisms most frequently involved in human Respiratory Tract Infections (RTIs) have been in the market for several decades, and at present, several different brands are available in many countries worldwide. They all claimed to exert local and systemic immunomodulatory effects but different clinical trials show disparate results between them. The lack of consistency of predicted therapeutic effects has undermined their clinical use and hampered licensing in several countries. One explanation for such lack of consistency in the results is that their methods of preparation are also very different. Here, we review the available literature describing methods of preparation of bacterial lysates, including patent disclosure documents. We found a great variety of methodologies of preparation and a lack of standardized procedures among them. The main conclusion of our study is that there is a clear need for standardized protocols of production to obtain comparable results in clinical trials worldwide.
由最常引发人类呼吸道感染(RTIs)的微生物制备的细菌裂解物已在市场上销售了几十年,目前,全球许多国家都有几种不同的品牌。它们都声称具有局部和全身免疫调节作用,但不同的临床试验显示它们之间的结果存在差异。预测治疗效果缺乏一致性削弱了它们的临床应用,并阻碍了在一些国家的许可。结果缺乏一致性的一个解释是它们的制备方法也非常不同。在这里,我们回顾了描述细菌裂解物制备方法的现有文献,包括专利公开文件。我们发现了各种各样的制备方法,并且它们之间缺乏标准化程序。我们研究的主要结论是,显然需要标准化的生产方案,以便在全球范围内的临床试验中获得可比的结果。